Presentation (CTI)

OBJECTIVES: Before any Joint Clinical Assessment begins, a dossier must be declared complete but is that a tick-box or a first verdict? This study examined whether the completeness determination is an administrative validation exercise or an early-stage scientific evaluation with significant consequences for market access and procedural rights.
METHODS: A legal and procedural analysis was conducted using Articles 9 and 10 of Regulation (EU) 2021/2282, Implementing Regulation (EU) 2024/1381, stakeholder position papers, and comparative regulatory frameworks. The completeness process was analysed against established concepts of administrative validation and scientific review within European regulatory systems.
RESULTS: The review found that the completeness gateway occupies an ambiguous position between administrative verification and substantive scientific assessment. While formally presented as a validation exercise, completeness evaluations may depend on whether evidence has been analysed using "appropriate methods," a criterion requiring scientific judgement rather than objective verification. Consequently, manufacturers may be required to address substantive methodological concerns within procedural timelines originally designed for administrative remediation. This hybrid function creates uncertainty regarding applicable standards, the scope of reviewer discretion, and the opportunities available to challenge adverse determinations. Stakeholder evidence further suggests that deficiencies identified at this stage may have substantial downstream consequences for assessment progression and product access.
CONCLUSIONS: The completeness gateway is among the most consequential yet least scrutinised steps in the JCA process. Clearer thresholds, transparency about what "complete" requires, and a route for dialogue would keep the gate fair without lowering submission quality.